Abdominal Obesity and Icosapent Ethyl Among Patients With Elevated Triglycerides

Slim man measuring his waist. Healthy lifestyle, body slimming, weight loss concept. Cares about body.
A study was conducted to determine if icosapent ethyl is effected by patient baseline abdominal obesity.

The following article is a part of conference coverage from the American College of Cardiology’s 71st Annual Scientific Session & Expo being held in Washington, DC, from April 2 to 4, 2022. The team at Cardiology Advisor will be reporting on the latest news and research conducted by clinicians and scientists in the field. Check back for more from the ACC 2022 .


Icosapent ethyl (IPE) was found to reduce cardiovascular (CV) events among patients with elevated triglycerides, according to study results presented at the American College of Cardiology 71st Annual Scientific Session & Expo, from April 2nd through 4th, in Washington, DC.

For this study, data were sourced from the randomized REDUCE-IT trial. Patients (N=8179) who were receiving statins for elevated triglycerides were randomly assigned to receive IPE or placebo. Efficacy of IPE to reduce the composite primary (CV death, myocardial infarction, coronary revascularization, and hospitalization for unstable angina) and secondary (CV death, myocardial infarction, and stroke) outcomes were assessed on the basis of waist circumference tertiles.

Among all study participants, IPE decreased risk for the primary composite outcome (hazard ratio [HR], 0.75; 95% CI, 0.68-0.83; P <.0001). Stratified by waist circumference, IPE decreased risk by a similar degree for those with the lowest tertile (£100 cm; HR, 0.74; 0.62-0.89; P =.001), intermediate tertile (>100-£111 cm; HR, 0.78; 95% CI, 0.65-0.93; P =.005), and highest tertile (>111 cm; HR, 0.76; 95% CI, 0.64-0.89; P =.0008) of abdominal obesity status.

Similarly, IPE decreased risk for the secondary composite outcome (HR, 0.74; 95% CI, 0.65-0.83; P <.0001). The protective effect of IPE was observed among the lowest tertile (HR, 0.78; 95% CI, 0.62-0.97; P =.03), intermediate tertile (HR, 0.72; 95% CI, 0.58-0.89; P =.003), and highest tertile (HR, 0.73; 95% CI, 0.60-0.90; P =.002) of waist circumference.

Overall, there was no waist circumference interaction for either the primary (P =.94) or secondary (P =.88) composite endpoints.

This analysis may have been limited as it was a post-hoc analysis of clinical trial data which was not expressly designed to evaluate the interaction between IPE and abdominal obesity.

“IPE significantly reduced CV events in patients regardless of baseline waist circumference,” the researchers noted. “These data suggest that the benefits of IPE in patients with elevated triglycerides are independent of the degree of baseline.”


Bhatt DL, Brinton EA, Miller M, et al. Icosapent ethyl reduces cardiovascular risk substantially and consistently regardless of waist circumference. Presented at: American College of Cardiology 71st Annual Scientific Session & Expo; April 2-4, 2022; Washington, DC

Visit Cardiology Advisor’s conference section for complete coverage of ACC 2022.